Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Jiangsu Hengrui Out-Licenses Novel Dermatology Drug for $233 Million

publication date: Jan 5, 2018

Jiangsu Hengrui Medicine out-licensed ex-China rights for a novel JAK inhibitor to Arcutis Pharma, a California dermatology company, in a deal worth up to $233 million, plus royalties. Arcutis will have rights to SHR0302 to treat dermatology disorders in the US, Europe and Japan. Hengrui is testing SHR0302 in a China Phase II trial for rheumatoid arthritis, though its agreement with Arcutis includes only topical use of the drug for dermatology diseases. More details....

Stock Symbol: (SHA: 600276)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.